S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)

Vanda Pharmaceuticals - VNDA Stock Forecast, Price & News

$10.29
+0.17 (+1.68%)
(As of 10/4/2022 05:20 PM ET)
Add
Compare
Today's Range
$10.10
$10.32
50-Day Range
$9.44
$11.35
52-Week Range
$9.24
$21.44
Volume
339,524 shs
Average Volume
505,424 shs
Market Capitalization
$582.01 million
P/E Ratio
51.45
Dividend Yield
N/A
Price Target
$12.00

Vanda Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
16.6% Upside
$12.00 Price Target
Short Interest
Bearish
4.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
1.87mentions of Vanda Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$61,585 Sold Last Quarter
Proj. Earnings Growth
31.82%
From $0.22 to $0.29 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

221st out of 1,087 stocks

Pharmaceutical Preparations Industry

96th out of 546 stocks

VNDA stock logo

About Vanda Pharmaceuticals (NASDAQ:VNDA) Stock

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Receive VNDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VNDA Stock News Headlines

Vanda Pharmaceuticals Tops Q1 EPS by 12c
Earnings Outlook For Vanda Pharmaceuticals
Why Are Vanda Pharma Shares Plunging Today?
See More Headlines
Receive VNDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VNDA Company Calendar

Last Earnings
8/03/2022
Today
10/04/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:VNDA
CUSIP
92165910
Employees
278
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+16.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$33.15 million
Pretax Margin
5.92%

Debt

Sales & Book Value

Annual Sales
$268.68 million
Cash Flow
$0.70 per share
Book Value
$9.06 per share

Miscellaneous

Free Float
52,602,000
Market Cap
$582.01 million
Optionable
Optionable
Beta
0.48

Social Links


Key Executives

  • Dr. Mihael H. Polymeropoulos M.D. (Age 62)
    Founder, Pres, CEO & Chairman of The Board
    Comp: $1.4M
  • Mr. Kevin Patrick Moran (Age 38)
    Sr. VP, CFO & Treasurer
    Comp: $615.51k
  • Mr. Timothy Williams (Age 46)
    Sr. VP, Gen. Counsel & Sec.
    Comp: $675.67k
  • Mr. Joakim  WijkstromMr. Joakim Wijkstrom (Age 56)
    Sr. VP & Chief Marketing Officer
    Comp: $779.67k
  • Mr. Gunther Birznieks (Age 52)
    Sr. VP of Bus. Devel.
    Comp: $644.4k
  • Mr. Scott L. Howell
    Chief People Officer
  • Ms. Elizabeth Van Every
    Head of Corp. Affairs













VNDA Stock - Frequently Asked Questions

Should I buy or sell Vanda Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" VNDA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VNDA, but not buy additional shares or sell existing shares.
View VNDA analyst ratings
or view top-rated stocks.

What is Vanda Pharmaceuticals' stock price forecast for 2022?

1 equities research analysts have issued 1 year price targets for Vanda Pharmaceuticals' stock. Their VNDA share price forecasts range from $12.00 to $12.00. On average, they anticipate the company's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 16.6% from the stock's current price.
View analysts price targets for VNDA
or view top-rated stocks among Wall Street analysts.

How have VNDA shares performed in 2022?

Vanda Pharmaceuticals' stock was trading at $15.69 at the start of the year. Since then, VNDA stock has decreased by 34.4% and is now trading at $10.29.
View the best growth stocks for 2022 here
.

When is Vanda Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our VNDA earnings forecast
.

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced its quarterly earnings data on Wednesday, August, 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by $0.06. The biopharmaceutical company had revenue of $64.39 million for the quarter, compared to the consensus estimate of $67 million. Vanda Pharmaceuticals had a net margin of 4.18% and a trailing twelve-month return on equity of 2.19%.

What guidance has Vanda Pharmaceuticals issued on next quarter's earnings?

Vanda Pharmaceuticals updated its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $240.00 million-$280.00 million, compared to the consensus revenue estimate of $265.10 million.

What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO?

12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX).

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $10.29.

How much money does Vanda Pharmaceuticals make?

Vanda Pharmaceuticals (NASDAQ:VNDA) has a market capitalization of $582.01 million and generates $268.68 million in revenue each year. The biopharmaceutical company earns $33.15 million in net income (profit) each year or $0.20 on an earnings per share basis.

How many employees does Vanda Pharmaceuticals have?

The company employs 278 workers across the globe.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The official website for the company is www.vandapharma.com. The biopharmaceutical company can be reached via phone at (202) 734-3400, via email at pr@vandapharma.com, or via fax at 202-296-1450.

This page (NASDAQ:VNDA) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.